In a major development, Russia's sovereign wealth fund and Indian pharmaceutical company Hetero have agreed to produce over 100 million doses per year in India of the Sputnik-V vaccine against COVID-19, according to a statement on the Sputnik V Twitter account on Friday.

The Russian Sputnik V vaccine against Covid-19 will be tested in India on 100 volunteers, the Indian Central Drugs Standard Control Organisation's Drug Controller General told Sputnik on Thursday.

As per reports, Hetero and the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, plan to start the production of Sputnik V in India at the beginning of 2021. Phase second and Third trials are ongoing in India, as per the statement.  India’s pioneer drug company  Dr. Reddy's Laboratories Ltd has said it expects late-stage trials to be completed by as early as March 2021.

Last week, the expert committee of the Drug Controller General had recommended granting permission to Dr Reddy's Laboratories for conducting phase 2 clinical trials of Russian Covid-19 vaccine candidate, Sputnik V, in India.

PM Modi will visit these cities tomorrow to take stock of corona vaccine development

PM Modi to visit Serum Institute on November 28 to take stock of Covishield vaccine

Health dept hopes arrival of Corona vaccine by January